News Center

Company news

Media reports

17

2015-07

Suzhou Kintor’s New Anti-Cancer Drug, Proxalutamide, Receives Special Funding for Significant Novel Drugs Development in the “National 13th Five-Year Plan”

Recently, a new-generation AR antagonist, proxalutamide, independently developed by Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor") receives initiation funding for special project of significant novel drugs development in "13th Five-Year plan".

Picture Name
< 1...19202122 > proceed page

Kintor